From: Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
Comorbidities, n (%) | All patients (N = 172) |
---|---|
Psychiatric disorders | 53 (31) |
Depression (including MDD) | 32 (19) |
Anxiety disorders (including GAD) | 36 (21) |
Depression and anxiety | 19 (11) |
Panic disorder | 2 (1) |
Bipolar spectrum disorders | 8 (5) |
Pain | 63 (37) |
Fibromyalgia | 16 (9) |
Chronic pain | 36 (21) |
Back pain | 33 (19) |
Neck pain | 28 (16) |
Sleep disorders | 41 (24) |
Insomnia | 39 (23) |
Restless leg syndrome | 4 (2) |
Sleep apnea | 18 (10) |
Digestive disorders | 28 (16) |
Irritable bowel syndrome | 2 (1) |
Constipation | 9 (5) |
Ulcer | 20 (12) |
Gastroesophageal reflux disease | 19 (11) |
Respiratory disorders | 29 (17) |
Allergies | 10 (6) |
Sinusitis | 11 (6) |
Bronchitis | 2 (1) |
Asthma | 17 (10) |
Cardiovascular disorders | 38 (22) |
Hypertension | 28 (16) |
High cholesterol | 15 (9) |
Stroke | 1 (1) |
Mitral valve prolapse | 1 (1) |
Postural orthostatic tachycardia syndrome | 2 (1) |
Neurologic disorders | 8 (5) |
Epilepsy | 8 (5) |
Autoimmune disorder | 2 (1) |
Rheumatoid arthritis | 2 (1) |
Hormonal disorder | 1 (1) |
Polycystic ovarian syndrome | 1 (1) |
Endocrine disorder | 21 (12) |
Diabetes | 16 (9) |
Hypothyroidism | 7 (4) |
Metabolic disorders | 18 (10) |
Obesity | 18 (10) |